Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus–Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy

BACKGROUND: Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health Organization–recommended standard of care in resource-limited settings, but the mechanism of CPT’s beneficial effects is unclear. The COSTOP trial (ISRCTN44723643) evaluated the nonin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyosiimire-Lugemwa, Jacqueline, Anywaine, Zacchaeus, Abaasa, Andrew, Levin, Jonathan, Gombe, Ben, Musinguzi, Kenneth, Kaleebu, Pontiano, Grosskurth, Heiner, Munderi, Paula, Pala, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336573/
https://www.ncbi.nlm.nih.gov/pubmed/31714954
http://dx.doi.org/10.1093/infdis/jiz494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336573/
https://www.ncbi.nlm.nih.gov/pubmed/31714954
http://dx.doi.org/10.1093/infdis/jiz494

Ejemplares similares